SCHEMBL23645514

SCHEMBL23645514

OCc1cccc(F)c1C1(CO)CCCC(OCc2ccccc2)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
HDAC4 P56524 2/20 0.37
OPRM1 P35372 2/20 0.36
OPRL1 P41146 2/20 0.36
SIGMAR1 Q99720 3/20 0.35
GAA P10253 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSK P43235 1/20 0.34
EPHX2 P34913 1/20 0.33
SPHK2 Q9NRA0 1/20 0.32
SPHK1 Q9NYA1 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
HTR1A P08908 2/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
SLC6A3 Q01959 2/20 0.32
P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23645496 0.84 DPP4 (0.41) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL23645210 0.84 HDAC4 (0.41) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL23645698 0.82 HDAC4 (0.43) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL23645697 0.79 HDAC4 (0.39) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL30291457 0.75 DPP4 (0.41) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL23645516 0.75 DPP4 (0.41) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL23668821 0.72 OPRM1 (0.39) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL30291278 0.72 OPRM1 (0.39) DPP4HDAC4OPRM1OPRL1SIGMAR1
SCHEMBL22111662 0.70 OPRM1 (0.48) DPP4OPRM1OPRL1SIGMAR1CTSL
SCHEMBL23645676 0.69 HDAC4 (0.37) DPP4HDAC4OPRM1OPRL1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113087700-B Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2023-03-14 CN disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
WO-2021139748-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-15 WO disclosed
CN-113087700-A Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2021-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES KRAS, NRAS, HRAS DPP4 3662/4885HDAC4 3767/4885OPRM1 2886/4885
US-11312724-B2 Spirocyclic tetrahydroquinazolines KRAS, NRAS, HRAS DPP4 3662/4885HDAC4 3767/4885OPRM1 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.